Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Pfizer/BioNTech say Omicron-based COVID shots improve response vs that variant

Published 06/25/2022, 10:24 AM
Updated 06/25/2022, 10:25 AM
© Reuters. FILE PHOTO: Doses of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) are pictured at a booster clinic for 12 to 17-year-olds in Lansdale, Pennsylvania, U.S., January 9, 2022. REUTERS/Hannah Beier

By Michael Erman

NEW YORK (Reuters) - Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) said on Saturday that a booster dose of updated versions of their COVID-19 vaccine, modified specifically to combat the Omicron coronavirus variant, generated a higher immune response against that variant.

Advisors to the U.S. Food and Drug Administration are scheduled to meet on Tuesday to discuss whether to update COVID-19 vaccines for the fall. The updated shots are likely to be redesigned to combat the Omicron variant of the coronavirus, experts say.

Pfizer and BioNTech said that 30 and 60 microgram doses of a shot targeting just the BA.1 Omicron subvariant that was circulating last winter elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against that subvariant. A version of the shot that contained both the redesigned vaccine and their original vaccine elicited a 9.1 and 10.9-fold increase, they said.

The results were from a trial of 1,234 people aged 56 or older. The shots were well-tolerated in participants, the companies said.

© Reuters. FILE PHOTO: Doses of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) are pictured at a booster clinic for 12 to 17-year-olds in Lansdale, Pennsylvania, U.S., January 9, 2022. REUTERS/Hannah Beier

They said that early laboratory studies suggest that both Omicron-modified candidates neutralize the Omicron BA.4 and BA.5 subvariants that have been circulating more recently, though to a lesser extent than they do for BA.1, with titers approximately 3-fold lower. The companies say they are continuing to collect data on how well the boosters perform versus the more recently circulating strains.

Moderna (NASDAQ:MRNA) Inc has also made a redesigned vaccine targeting the BA.1 Omicron subvariant. The company said its updated vaccine worked well against more recent Omicron subvariants, and that it was moving forward with plans to ask regulators for approval.

Latest comments

They want to give vaccines at the end of time. They don't want the cure.
🤡🤡🤡
stronger immune response - does it mean more antibodies? what happens once antibodies depleted? many people already had omicron. my personal experience and all people I know it was mild.
Do they really care…the only think they care about is make billions….
I think after 4 shots we have had enough of this Bull
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.